Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Markus Leweke

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
BMJ Open|January 23, 2023
Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trialJoanne S Carpenter, Natalia Zmicerevska, Jacob J Crouse, et al.
Translational Psychiatry|October 19, 2023
Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 densitySara L Kroll, Lea M Hulka, Ann-Kathrin Kexel, et al.
Elife|September 28, 2018
Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stagesTineke Grent-'t-Jong, Joachim Gross, Jozien Goense, et al.
NPJ Schizophrenia|June 24, 2016
Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorderEmily G Severance, Kristin L Gressitt, Catherine R Stallings, et al.
Focus (American Psychiatric Publishing)|January 31, 2020
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching AntipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Schizophrenia Bulletin|March 20, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 16, 2015
Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent BehaviorMiriam Schneider, Fernando Kasanetz, Diane L Lynch, et al.
Ebiomedicine|March 26, 2025
Cerebrospinal fluid metabolomics in autistic regression reveals dysregulation of sphingolipids and decreased β-hydroxybutyrateJingya Yan, Velda X Han, Hannah F Jones, et al.
BMJ Mental Health|August 25, 2024
Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteersTimothy A Couttas, Carola Boost, Franziska Pahlisch, et al.
The Medical Journal of Australia|November 4, 2019
Right care, first time: a highly personalised and measurement-based care model to manage youth mental healthIan B Hickie, Elizabeth M Scott, Shane P Cross, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
BMJ Open|January 23, 2023
Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trialJoanne S Carpenter, Natalia Zmicerevska, Jacob J Crouse, et al.
Translational Psychiatry|October 19, 2023
Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 densitySara L Kroll, Lea M Hulka, Ann-Kathrin Kexel, et al.
Elife|September 28, 2018
Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stagesTineke Grent-'t-Jong, Joachim Gross, Jozien Goense, et al.
NPJ Schizophrenia|June 24, 2016
Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorderEmily G Severance, Kristin L Gressitt, Catherine R Stallings, et al.
Focus (American Psychiatric Publishing)|January 31, 2020
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching AntipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Schizophrenia Bulletin|March 20, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 16, 2015
Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent BehaviorMiriam Schneider, Fernando Kasanetz, Diane L Lynch, et al.
Ebiomedicine|March 26, 2025
Cerebrospinal fluid metabolomics in autistic regression reveals dysregulation of sphingolipids and decreased β-hydroxybutyrateJingya Yan, Velda X Han, Hannah F Jones, et al.
BMJ Mental Health|August 25, 2024
Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteersTimothy A Couttas, Carola Boost, Franziska Pahlisch, et al.
The Medical Journal of Australia|November 4, 2019
Right care, first time: a highly personalised and measurement-based care model to manage youth mental healthIan B Hickie, Elizabeth M Scott, Shane P Cross, et al.
Pageof 12